473 related articles for article (PubMed ID: 28800461)
1. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
2. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.
Zhang H; Xin MH; Xie XX; Mao S; Zuo SJ; Lu SM; Zhang SQ
Bioorg Med Chem; 2015 Dec; 23(24):7765-76. PubMed ID: 26652969
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.
Mahmoud MAA; Alsharif MA; Mohareb RM
Anticancer Agents Med Chem; 2021; 21(4):468-486. PubMed ID: 32445457
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
9. Quinazolin-4(3
Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Ayyad RR; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
Bioorg Med Chem; 2021 Jan; 29():115872. PubMed ID: 33214036
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
Ma CC; Liu ZP
Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
Fan C; Zhong T; Yang H; Yang Y; Wang D; Yang X; Xu Y; Fan Y
Eur J Med Chem; 2020 Mar; 190():112108. PubMed ID: 32058239
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
Kim O; Jeong Y; Lee H; Hong SS; Hong S
J Med Chem; 2011 Apr; 54(7):2455-66. PubMed ID: 21388141
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K
Chen R; Wang Z; Sima L; Cheng H; Luo B; Wang J; Guo B; Mao S; Zhou Z; Peng J; Tang L; Liu X; Liao W
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2155638. PubMed ID: 36650905
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
